Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca(2+)-dependent proteolytic systems in the muscle of tumour-bearing rats.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cytokine

• Publication date

  2002-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1006/CYTO.2002.1036PMID 12200106
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: A pilot study

  2005cited by this paper
• Increased muscle ubiquitin mRNA levels in gastric cancer patients.

  2001cited by this paper
• Loss of skeletal muscle in cancer: biochemical mechanisms.

  2001cited by this paper
• Muscle Cachexia: Current Concepts of Intracellular Mechanisms and Molecular Regulation

  2001cited by this paper
• Activation of Ca2+-dependent proteolysis in skeletal muscle and heart in cancer cachexia

  2001cited by this paper
• Serum tumour necrosis factor‐α levels in cancer patients are discontinuous and correlate with weight loss

  2000cited by this paper
• Cancer cachexia: from experimental models to patient management.

  2000cited by this paper
• Implication of calpain in caspase activation during B cell clonal deletion

  1999cited by this paper
• Tumour growth and nitrogen metabolism in the host (Review).

  1999cited by this paper
• Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model

  1999cited by this paper
• Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats

  1999cited by this paper
• Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice.

  1998cited by this paper
• Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1.

  1998cited by this paper
• Proteasome activities decrease during dexamethasone-induced apoptosis of thymocytes.

  1998cited by this paper
• Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats.

  1996cited by this paper
• Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.

  1996cited by this paper
• Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma.

  1995cited by this paper
• Inhibition of experimental cancer cachexia by anti-cytokine and anti-cytokine-receptor therapy.

  1995cited by this paper
• Muscle wasting associated with cancer cachexia is linked to an important activation of the atp‐dependent ubiquitin‐mediated proteolysis

  1995cited by this paper
• Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway.

  1995cited by this paper
• Anti-tumour necrosis factor-alpha treatment interferes with changes in lipid metabolism in a tumour cachexia model.

  1994cited by this paper
• Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor-bearing rats.

  1994cited by this paper
• Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals.

  1993cited by this paper
• Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.

  1993cited by this paper
• Suramin induces deoligomerization of human tumor necrosis factor alpha.

  1993cited by this paper
• Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis.

  1993cited by this paper
• Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model.

  1993cited by this paper
• Ovine skeletal muscle multicatalytic proteinase complex (proteasome): purification, characterization, and comparison of its effects on myofibrils with mu-calpains.

  1992cited by this paper
• Abnormal substrate metabolism and nutritional strategies in cancer management.

  1991cited by this paper
• Anti-interferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia.

  1991cited by this paper
• Weight loss and nutritional abnormalities in cancer patients: incidence, severity and significance

  1986cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper
• THE IMMEDIATE CAUSES OF DEATH IN CANCER

  1932cited by this paper

• Histidine decarboxylase inhibition attenuates cancer-associated muscle wasting.

  2025cites this paper
• Combating muscle atrophy: emerging therapeutic targets that are fiber‐type‐specific

  2025cites this paper
• Pathogenesis of Sarcopenia in Chronic Kidney Disease—The Role of Inflammation, Metabolic Dysregulation, Gut Dysbiosis, and microRNA

  2024cites this paper
• Evidence for reciprocal network interactions between injured hearts and cancer

  2022cites this paper
• Breakdown of Filamentous Myofibrils by the UPS–Step by Step

  2021cites this paper
• The Redox Balance: A Target for Interventions Against Muscle Wasting in Cancer Cachexia?

  2020cites this paper
• THE EFFECT OF PERCUTANEOUS CORONARY INTERVENTION (PCI) WITH DES ON ANTITHROMBIN-III (AT-III) AND THROMBIN ANTITHROMBIN COMPLEX (TAT) IN CORONARY HEART DISEASE PATIENTS AT HAJI ADAM MALIK GENERAL HOSPITAL

  2020cites this paper
• The Regulation of Skeletal Muscle Protein Turnover During the Progression of Cancer Cachexia in the <em>Apc^Min/+</em> Mouse

  2020cites this paper
• Role of calpains in promoting desmin filaments depolymerization and muscle atrophy.

  2020cites this paper
• THE EFFECT OF OPHIOCEPHALUS STRIATUS EXTRACT ON SERUM LEPTIN LEVEL OF CANCER CACHEXIA PATIENTS

  2020cites this paper
• The Regulation of Skeletal Muscle Protein Turnover During the Progression of Cancer Cachexia in the Apc Min / + Mouse

  2019cites this paper
• Animal models of cancer-associated cachexia

  2019cites this paper
• The Skeletal Muscle as an Active Player Against Cancer Cachexia

  2019cites this paper
• Modulating Metabolism to Improve Cancer-Induced Muscle Wasting

  2018cites this paper
• Breast cancer-released exosomes trigger cancer-associated cachexia to promote tumor progression

  2018cites this paper
• Rôle de médiateurs de l'inflammation dans l'altération de la fonction musculaire : étude des effets du sepsis et de la chimiothérapie sur un modèle murin

  2017cites this paper
• Effekte pharmakologischer Interventionen auf Muskelatrophie im Mausmodell der amyotrophen Lateralsklerose (ALS)

  2017cites this paper
• Interference with Ca2+-Dependent Proteolysis Does Not Alter the Course of Muscle Wasting in Experimental Cancer Cachexia

  2017cites this paper
• Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs

  2016cites this paper
• Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia – can findings from animal models be translated to humans?

  2016cites this paper
• Identification of PDLIM7 as a Nedd4-1 substrate in the regulation of skeletal muscle mass

  2016cites this paper
• Hsp 60 levels and mitochondrial biogenesis in skeletal muscle after endurance training TRIENNIO 2013-2015

  2016cites this paper
• The effect of thalidomide on cachexia in upper gastrointestinal cancer

  2015cites this paper
• Effect of the specific proteasome inhibitor bortezomib on cancer‐related muscle wasting

  2015cites this paper
• Whey-hydrolyzed peptide-enriched immunomodulating diet prevents progression of liver cirrhosis in rats.

  2014cites this paper
• Mechanism-based therapeutic approaches to cachexia.

  2013cites this paper
• Antioxidant Treatment of Muscle Wasting and Fatigue in Tumor-Bearing Mice

  2013cites this paper
• Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients.

  2013cites this paper
• Invalidation du gène de la myostatine dans un modèle murin de cachexie associée au cancer : implication dans la régulation de la masse musculaire

  2013cites this paper
• Autophagic degradation contributes to muscle wasting in cancer cachexia.

  2013cites this paper
• MUSCLE WASTING AND CARDIAC MUSCLE DAMAGE IN CACHECTIC PATIENTS

  2013cites this paper
• The Role of IL-6 and Myogenic Transcription Factors in Skeletal Muscle Wasting and Dysfunction Due to Cancer Cachexia

  2013cites this paper
• Motor protein function in skeletal abdominal muscle of cachectic cancer patients

  2013cites this paper
• Demystifying fatigue in Crohn’s disease:assessing prevalence, pathogenic and contributing factors for clinical application

  2012cites this paper
• Cancer cachexia: impact, mechanisms and emerging treatments

  2012cites this paper
• The “parallel pathway”: a novel nutritional and metabolic approach to cancer patients

  2011cites this paper
• Dcancet inflammation : effet des acides gras polyinsatur es n-3

  2011cites this paper
• Glutamine prevents myostatin hyperexpression and protein hypercatabolism induced in C2C12 myotubes by tumor necrosis factor-α

  2011cites this paper
• Cancer anorexia and cachexia

  2011cites this paper
• The Regulation of Skeletal Muscle Protein Turnover during the Progression of Cancer Cachexia in the ApcMin/+ Mouse

  2011cites this paper
• Dénutrition cancéreuse et inflammation : effet des acides gras polyinsaturés n-3

  2011cites this paper
• CALPAIN activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss

  2011cites this paper
• β-hydroxy-β-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia.

  2011cites this paper
• Anti-cytokine strategies for the treatment of cancer-related anorexia and cachexia

  2010cites this paper
• Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies.

  2010cites this paper
• Time course of skeletal muscle loss and oxidative stress in rats with walker 256 solid tumor

  2010cites this paper
• Are tumoral factors responsible for host tissue wasting in cancer cachexia?

  2010cites this paper
• Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic ApcMin/+ mouse

  2009cites this paper
• Inter-relações e variabilidade do estado nutricional, colesterolemia, actividade neuro-humoral e pró-inflamatória na Insuficiência Cardíaca

  2009cites this paper
• The effects of pentoxifylline on skeletal muscle contractility and neuromuscular transmission during hypoxia

  2009cites this paper
• Cardiac cachexia: a systematic overview.

  2009cites this paper
• The cytokine basis of cachexia and its treatment: are they ready for prime time?

  2008cites this paper
• Positive and negative modulation of peptidases by pro-inflammatory cytokines.

  2008cites this paper
• Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia

  2008cites this paper
• Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia.

  2008cites this paper
• Formoterol fumarate and roxithromycin effects on muscle mass in an animal model of cancer cachexia.

  2008cites this paper
• Highlights on Cachexia, from the 4th Cachexia Conference, Tampa (FL), 6-9 Dec 2007

  2008cites this paper
• Calpain activity and muscle wasting in sepsis.

  2008cites this paper
• The Biological Mechanisms of Cancer-Related Skeletal Muscle Wasting: The Role of Progressive Resistance Exercise

  2008influential citation
• Skeletal muscle in cancer cachexia: the ideal target of drug therapy.

  2008cites this paper
• Muscle myostatin signalling is enhanced in experimental cancer cachexia

  2008cites this paper
• Interleukin-6 modulates hepatic and muscle protein synthesis during hemodialysis.

  2008cites this paper
• Mechanisms of Cachexia

  2007cites this paper
• Nutritional Support in Cancer

  2007cites this paper
• Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy.

  2007cites this paper
• CYCLIC ADENOSINE MONOPHOSPHATE-PHOSPHODIESTERASE INHIBITORS REDUCE SKELETAL MUSCLE PROTEIN CATABOLISM IN SEPTIC RATS

  2007cites this paper
• Novel treatments for cancer cachexia

  2007cites this paper
• The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia.

  2007cites this paper
• Cancer Cachexia: It’s Time for More Clinical Trials

  2007cites this paper
• Métabolisme énergétique au cours de la cachexie cancereuse

  2007cites this paper
• Physiopathologie de la cachexie cancéreuse

  2007cites this paper
• The Ubiquitin/Proteasome System in Cancer Cachexia

  2006cites this paper
• Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF‐κB‐independent, FoxO1‐dependent mechanism

  2006cites this paper
• The AP‐1/CJUN signaling cascade is involved in muscle differentiation: Implications in muscle wasting during cancer cachexia

  2006cites this paper
• Inflammatory factors in age-related muscle wasting

  2006cites this paper
• Skeletal muscle apoptosis is not increased in gastric cancer patients with mild-moderate weight loss.

  2006cites this paper
• Effects of Tumor Necrosis Factor-Alpha on the 26S Proteasome and 19S Regulator in Skeletal Muscle of Severely Scalded Mice

  2006cites this paper
• Prevention and treatment of cancer cachexia: new insights into an old problem.

  2006cites this paper
• IGF-1 is downregulated in experimental cancer cachexia.

  2006cites this paper
• Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism.

  2006cites this paper
• Energy homeostasis and cachexia in chronic kidney disease

  2006cites this paper
• Development of a sandwich ELISA assay for measuring bovine soluble type II IL-1 receptor (IL1R2) concentration in serum and milk.

  2005cites this paper
• Molecular pathways leading to cancer cachexia.

  2005cites this paper
• The Ubiquitin-Proteasome Pathway

  2005cites this paper
• Indomethacin preserves muscle mass and reduces levels of E3 ligases and TNF receptor type 1 in the gastrocnemius muscle of tumor-bearing mice.

  2005cites this paper
• Anorexia and Cachexia

  2005cites this paper
• Ca(2+)-dependent proteolysis in muscle wasting.

  2005cites this paper
• Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group

  2005cites this paper
• Conjugated linoleic acid preserves gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma.

  2005cites this paper
• Cytokine-related aging process.

  2004cites this paper
• Therapy of muscle wasting in cancer: what is the future?

  2004cites this paper
• Role of NF-κB and cytokine in experimental cancer cachexia

  2003cites this paper
• Effects of simvastatin administration in an experimental model of cancer cachexia.

  2003cites this paper
• Role of NF-kappaB and cytokine in experimental cancer cachexia.

  2003cites this paper
• Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP‐ubiquitin‐dependent proteolysis

  2003cites this paper
• Rethinking Nutritional Support for Persons with Cancer Cachexia

  2003cites this paper
• The role of the ubiquitin/proteasome system in cellular responses to radiation

  2003cites this paper